Compare AKAN & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKAN | AEMD |
|---|---|---|
| Founded | 2021 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.1M |
| IPO Year | 2021 | 2008 |
| Metric | AKAN | AEMD |
|---|---|---|
| Price | $3.44 | $1.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 790.4K | ★ 1.5M |
| Earning Date | 05-12-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $0.51 |
| 52 Week High | $78.90 | $5.89 |
| Indicator | AKAN | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.61 | 40.16 |
| Support Level | $0.67 | $1.36 |
| Resistance Level | $3.40 | $2.47 |
| Average True Range (ATR) | 0.48 | 0.26 |
| MACD | 0.13 | -0.15 |
| Stochastic Oscillator | 3.15 | 4.94 |
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.